India Daily Briefing

SEBI identified and penalized two entities for manipulative trades executed during Cash Settlement (CAS) on Sensex expiry day, ordering recovery of ₹3.68 Crore. The order signals SEBI's intensifying surveillance of derivative expiry-day microstructure — a direct warning to HFT desks running index-arbitrage strategies around monthly expiry. Expect stricter position-limit monitoring in the next quarterly review.

Goldman Sachs accumulated over 40 lakh Shiprocket shares at its D-Street debut — a strong institutional endorsement for India's logistics-technology IPO pipeline. Shiprocket, which counts Temasek among its backers, listed at a US$1 billion valuation and the Goldman position signals conviction in India's e-commerce fulfilment infrastructure story. This could re-rate comparable listed names in the warehousing and last-mile delivery segment.

Symbiotec Pharmalab's ₹1,757 Crore IPO filing adds to an increasingly active pharma IPO calendar in H2 FY27. The company operates in the pharmaceutical ingredients segment, where domestic production capacity expansion has been a policy priority since PLI scheme rollout. With Pharma -0.18% in today's session and India VIX at multi-month low 11.32, IPO grey market activity is likely to be constructive for the sector.